SCHEMBL6118366

SCHEMBL6118366

[2H]C([2H])([2H])OCC(C)OS(=O)(=O)c1ccc(C)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.37
GBA1 P04062 1/20 0.36
ALDH1A1 P00352 7/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
DHODH Q02127 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
CA2 P00918 4/20 0.36
CA9 Q16790 3/20 0.36
CA12 O43570 2/20 0.36
VDR P11473 1/20 0.36
TSHR P16473 1/20 0.36
RECQL P46063 1/20 0.35
CA1 P00915 3/20 0.35
CA7 P43166 2/20 0.35
CA3 P07451 1/20 0.35
CA6 P23280 1/20 0.35
CA5A P35218 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30001425 0.89 ALDH1A1 (0.43) GAAGBA1ALDH1A1CYP3A4CYP2C9
SCHEMBL320440 0.89 ALDH1A1 (0.43) GAAGBA1ALDH1A1CYP3A4CYP2C9
SCHEMBL320439 0.89 ALDH1A1 (0.43) GAAGBA1ALDH1A1CYP3A4CYP2C9
SCHEMBL6118689 0.89 ALDH1A1 (0.43) GAAGBA1ALDH1A1CYP3A4CYP2C9
SCHEMBL21798639 0.87 ALDH1A1 (0.42) GAAGBA1ALDH1A1CYP3A4CYP2C9
SCHEMBL1148936 0.82 GAA (0.41) GAAGBA1ALDH1A1CYP3A4CYP2C9
SCHEMBL2337309 0.82 GAA (0.41) GAAGBA1ALDH1A1CYP3A4CYP2C9
SCHEMBL17404667 0.80 GAA (0.45) GAAGBA1ALDH1A1CYP3A4CYP2C9
SCHEMBL5245093 0.80 GBA1 (0.46) GAAGBA1ALDH1A1CYP3A4CYP2C9
SCHEMBL5830519 0.80 GBA1 (0.46) GAAGBA1ALDH1A1CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130324530-A1 3-(AMINOARYL)-PYRIDINE COMPOUNDS NOVARTIS AG 2013-12-05 US disclosed
EP-2668162-A1 SUBSTITUTED BI-HETEROARYL COMPOUNDS AS CDK9 INHIBITORS AND THEIR USES Novartis AG (CH) 2013-12-04 EP disclosed
US-20130303507-A1 SUBSTITUTED HETERO-BIARYL COMPOUNDS AND THEIR USES NOVARTIS AG (CH) 2013-11-14 US disclosed
US-20130303507-A1 SUBSTITUTED HETERO-BIARYL COMPOUNDS AND THEIR USES NOVARTIS AG (CH) 2013-11-14 US disclosed
EP-2640702-A1 3-(AMINOARYL)-PYRIDINE COMPOUNDS Novartis AG (CH) 2013-09-25 EP disclosed
WO-2012101065-A2 PYRIMIDINE BIARYL AMINE COMPOUNDS AND THEIR USES NOVARTIS AG (CH) 2012-08-02 WO disclosed
WO-2012101066-A1 PYRIDINE BIARYL AMINE COMPOUNDS AND THEIR USES NOVARTIS AG (CH) 2012-08-02 WO disclosed
WO-2012101062-A1 SUBSTITUTED BI-HETEROARYL COMPOUNDS AS CDK9 INHIBITORS AND THEIR USES NOVARTIS AG (CH) 2012-08-02 WO disclosed
WO-2012066065-A1 PHENYL-HETEROARYL AMINE COMPOUNDS AND THEIR USES NOVARTIS AG (CH) 2012-05-24 WO disclosed
WO-2012066070-A1 3-(AMINOARYL)-PYRIDINE COMPOUNDS NOVARTIS AG (CH) 2012-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130324530-A1 3-(AMINOARYL)-PYRIDINE COMPOUNDS CDK9, CDK19, CDK3 GAA 1354/4885GBA1 3131/4885ALDH1A1 1949/4885
US-20130303507-A1 SUBSTITUTED HETERO-BIARYL COMPOUNDS AND THEIR USES CDK9, CDK19, CDK3 GAA 2215/4885GBA1 1878/4885ALDH1A1 2220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.